{"id":"metformin-hci-xr","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Gastrointestinal disturbance (diarrhea, nausea, vomiting)"},{"rate":"3-10","effect":"Metallic taste"},{"rate":"5-15","effect":"Abdominal discomfort"},{"rate":"<0.1","effect":"Lactic acidosis (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Metformin is a biguanide that primarily works by decreasing gluconeogenesis in the liver and increasing peripheral glucose uptake and utilization. The extended-release (XR) formulation allows for once-daily dosing with improved gastrointestinal tolerability compared to immediate-release formulations. It does not stimulate insulin secretion, making it suitable for use across various stages of type 2 diabetes.","oneSentence":"Metformin HCl XR reduces hepatic glucose production and improves insulin sensitivity to lower blood glucose levels in type 2 diabetes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:57.280Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06246799","phase":"PHASE3","title":"Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-11-07","conditions":"Type 2 Diabetes (Adult Onset)","enrollment":256}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Extended Release Metformin"],"phase":"phase_3","status":"active","brandName":"Metformin HCI XR","genericName":"Metformin HCI XR","companyName":"The University of Texas Health Science Center at San Antonio","companyId":"the-university-of-texas-health-science-center-at-san-antonio","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metformin HCl XR reduces hepatic glucose production and improves insulin sensitivity to lower blood glucose levels in type 2 diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}